69875-54-3

Usage

Uses

Used in Pharmaceutical Industry:
3-Cyano-2,4-dichloroquinoline is used as an intermediate in the synthesis of various pharmaceuticals for its antifungal and antimicrobial properties. It aids in the development of new drugs that can effectively combat fungal and bacterial infections.
Used in Agrochemical Industry:
3-Cyano-2,4-dichloroquinoline is used as an intermediate in the synthesis of agrochemicals due to its insecticidal and antiparasitic activities. It contributes to the development of effective pesticides and treatments for protecting crops from pests and parasites.
Used in Medicinal Applications:
3-Cyano-2,4-dichloroquinoline is used as a potential active ingredient in the development of new medications targeting a wide range of infections and infestations, including those caused by fungi, bacteria, insects, and parasites. Its multifaceted properties make it a promising candidate for various therapeutic applications.

Upstream product

• 15000-43-8 2,4-dihydroxyquinoline-3-carbonitrile 
• 10026-13-8 phosphorus pentachloride 
• 10025-87-3 trichlorophosphate 
• 128366-07-4 4-hydroxy-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid cyclohexylamide 
• 621-03-4 cyanoacetanilide 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 118-48-9 isatoic anhydride 
• 103-71-9 phenyl isocyanate 
• 1356125-45-5 3-cyano-2,4-dioxo-tetrahydroquinoline 
• 2651-12-9 ethyl 2-cyano-3-oxo-3-(phenylamino)-propanoate 
• 15000-43-8 4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonitrile 

Downstream Products

• 34846-64-5 3-cyanoquinoline 
• 157027-31-1 4-azido-2-chloroquinoline-3-carbonitrile 
• 246546-72-5 2-Chloro-4-(cyclohexylamino)quinoline-3-carbonitrile 
• 246546-77-0 2-Chloro-4-[(4-methylphenyl)amino]quinoline-3-carbonitrile 
• 246546-78-1 2-Chloro-4-[(4-methoxyphenyl)amino]quinoline-3-carbonitrile 
• 246546-76-9 4-Anilino-2-chloroquinoline-3-carbonitrile 
• 246546-79-2 2-Chloro-4-[(3-methylphenyl)amino]quinoline-3-carbonitrile 
• 246546-73-6 4-Benzylamino-2-chloroquinoline-3-carbonitrile 
• 353507-18-3 3-amino-4-chloro-1-phenylpyrazolo[4,3-c]quinoline 
• 876134-52-0 4-amino-2-triphenylphosphoranylideneaminoquinoline-3-carbonitrile 
• 876134-51-9 5-(triphenylphosphoranylideneamino)tetrazolo[1,5-a]quinoline-4-carbonitrile 
• 876134-48-4 2,4-bis(triphenylphosphoranylideneamino)quinoline-3-carbonitrile 
• 212378-26-2 2-chloro-4-(triphenylphosphoranylideneamino)quinoline-3-carbonitrile 
• 860454-34-8 ethyl 3-amino-4-(cyclohexylamino)thieno[3,2-c]quinoline-2-carboxylate 

Relevant academic research and scientific papers

Synthesis method of 2,4-dichloroquinoline compound

The invention discloses a synthesis method of a 2,4-dichloroquinoline compound, belonging to the technical field of organic synthesis. The method comprises the following steps: at room temperature, mixing triphosgene and triphenylphosphine oxide, dissolving the mixture in an organic solvent, stirring for 10-30 minutes, adding an alpha-substituted acetyl arylamine compound, heating the reaction system to 90-130 DEG C, continuously stirring and reacting for 3-6 hours, and post-treating the obtained reaction liquid to obtain the 2,4-dichloroquinoline compound. The method for synthesizing the 2, 4-dichloroquinoline compound has the advantages of few steps, high yield and safer and more convenient operation; meanwhile, the triphenylphosphine oxide used in the reaction can be recycled, so that the emission of phosphorus-containing wastes is greatly reduced, and the method is suitable for industrial production.

PHENYL-CYANOQUINOLINONE PDE9 INHIBITORS

The present invention is directed to phenylcyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use

AZA-CYANOQUINOLINONE PDE9 INHIBITORS

The present invention is directed to azacyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

OXY-CYANOQUINOLINONE PDE9 INHIBITORS

The present invention is directed to oxycyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of

Design, synthesis, and biological evaluation of new diaminoquinazolines as β-catenin/Tcf4 pathway inhibitors

More than 50 new diaminoquinazoline derivatives have been synthesized and evaluated in a colon carcinoma cell growth inhibition assay using HCT116 and SW480 cells. Twenty compounds with good cell growth inhibitory activities (50 values 50 values of 1.5-2.5 μM for HCT116 cells with the luciferase reporter assay.

MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH

The present invention provides screening methods for identifying modifiers of chemosensory receptors and their ligands, e.g., by determining whether a test entity is suitable to interact with one or more interacting sites within the Venus flytrap domains of the chemosensory receptors as well as modifiers capable of modulating chemosensory receptors and their ligands.

PHENYL-SUBSTITUTED QUINOLINE AND QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF DIABETES

The invention relates to 2-phenyl-substituted quinoline and quinazoline compounds, pharmaceutical compositions, and methods for treating diabetes and related disorders.

Synthesis of some novel azido- and tetrazoloquinoline-3-carbonitriles and their conversion into 2,4-diaminoquinoline-3-carbonitriles

Quinoline-3-carbonitriles carrying amino groups at the 2- and/or 4-position have been prepared via the corresponding azido- or tetrazolo-quinolines, through the intermediacy of phosphazenes.

INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND METHODS FOR IDENTIFYING THE SAME

Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures (Ia), (Ib) including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

Regioselective Azidation of 2,4-Dichloroquinolines

Reactions of 2,4-dichloroquinolines (2a-f) with sodium azide in DMF lead either regioselectively to 4-azido-2-chloroquinolines (3a-f) or with excess of sodium azide and catalysts to 5-azido-tetrazoloquinolines (4a-f). 2,4-Dichloroquinolines (2g-i) having electron donating substituents in 3-position react with sodium azide in DMF to a mixture of 4-azido-2-chloroquinolines (3g-i) and 5-chlorotetrazoloquinolines (5g-i).When the reaction of the 2,4-dichloroquinolines (2a-i) with sodium azide is carried out in ethanol with addition of methanesulfonic acid, regioselectively 5-chloro-tetrazoloquinolines (5a-i) are obtained.Structural assignments of 3 and 5 have been carried out by 13C-NMR spectra, IR spectra and degradation reactions of the azido- and tetrazolo group to aminoquinolines (7 and 10) via iminophosphoranes (8 and 9).It could be shown that in 2-azido/tetrazolo-quinolines (4 and 5) the tetrazole ring structure is the dominant species.